Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
72-80-0
Molecular formula
C10H7Cl2NO
Molecular weight
228.07 g/mol
Drug class
Local anti-infectivehydroxyquinoline antiseptic and fungistat
Mechanism of action
The exact antimicrobial mechanism is not fully established. Its activity is associated with the local anti-infective properties of the 8-hydroxyquinoline class and may involve interactions with microbial metal-dependent enzymes and cellular processes.
Indications / reported uses
Local treatment of selected skin, gastrointestinal and vaginal infections caused by susceptible fungi, protozoa and bacteria, where authorised.
Topical antiseptic or deodorant use in formulations authorised for the intended site.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Chlorquinaldol Environmental Risk Assessment (ERA) (the Chlorquinaldol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.